Literature DB >> 9246020

Human thiopurine methyltransferase pharmacogenetics: gene sequence polymorphisms.

D Otterness1, C Szumlanski, L Lennard, B Klemetsdal, J Aarbakke, J O Park-Hah, H Iven, K Schmiegelow, E Branum, J O'Brien, R Weinshilboum.   

Abstract

Thiopurine methyltransferase (TPMT) catalyzes the S-methylation of thiopurine drugs. TPMT activity is regulated by a common genetic polymorphism that is associated with large individual variations in thiopurine toxicity and efficacy. We previously cloned the functional gene for human TPMT and reported a common variant allele for low enzyme activity, TPMT*3A, that contains point mutations at cDNA nucleotides 460 and 719. In the present study, we set out to determine the number, types, and frequencies of TPMT variant alleles associated with low enzyme activity in clinical laboratory samples in the United States and to compare those results with data obtained from two different ethnic groups. We identified a total of six different variant alleles for low TPMT activity in the 283 clinical laboratory samples studied. The most common variant was *3A; the second most frequent variant allele, *3C, contained only the nucleotide 719 polymorphism; and four other variant alleles were detected. TPMT*3A also appeared to be the most common variant allele in a Norwegian white population sample, but it was not found in a population sample of Korean children. However, *3C was present in samples from the Korean children, as was novel allele, *6. Characterization of variant alleles for low TPMT enzyme activity will help make it possible to assess the potential clinical utility of deoxyribonucleic acid-based diagnostic tests for determining TPMT genotype.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9246020     DOI: 10.1016/S0009-9236(97)90152-1

Source DB:  PubMed          Journal:  Clin Pharmacol Ther        ISSN: 0009-9236            Impact factor:   6.875


  63 in total

Review 1.  Clinical pharmacology of inflammatory bowel disease therapies.

Authors:  W J Sandborn; W A Faubion
Journal:  Curr Gastroenterol Rep       Date:  2000-12

Review 2.  Part 1: background, methodology, and clinical adoption of pharmacogenetics.

Authors:  Maarten J Deenen; Annemieke Cats; Jos H Beijnen; Jan H M Schellens
Journal:  Oncologist       Date:  2011-05-31

Review 3.  Pharmacogenetics of drug metabolizing enzymes and transporters: effects on pharmacokinetics and pharmacodynamics of anticancer agents.

Authors:  Norman H Lee
Journal:  Anticancer Agents Med Chem       Date:  2010-10-01       Impact factor: 2.505

4.  Racial and ethnic categories in biomedical research: there is no baby in the bathwater.

Authors:  Mildred K Cho
Journal:  J Law Med Ethics       Date:  2006       Impact factor: 1.718

5.  TPMT genetic variants are associated with increased rejection with azathioprine use in heart transplantation.

Authors:  Jackson J Liang; Jennifer R Geske; Barry A Boilson; Robert P Frantz; Brooks S Edwards; Sudhir S Kushwaha; Walter K Kremers; Richard M Weinshilboum; Naveen L Pereira
Journal:  Pharmacogenet Genomics       Date:  2013-12       Impact factor: 2.089

6.  Association of thiopurine methyltransferase status with azathioprine side effects in Chinese patients with systemic lupus erythematosus.

Authors:  Dongying Chen; Fan Lian; Shiwen Yuan; Yixi Wang; Zhongping Zhan; Yujin Ye; Qian Qiu; Hanshi Xu; Liuqin Liang; Xiuyan Yang
Journal:  Clin Rheumatol       Date:  2013-12-10       Impact factor: 2.980

7.  Comparative pharmacogenetic analysis of risk polymorphisms in Caucasian and Vietnamese children with acute lymphoblastic leukemia: prediction of therapeutic outcome?

Authors:  Phuong Thu Vu Hoang; Jérôme Ambroise; Anne-France Dekairelle; Jean-François Durant; Valentina Butoescu; Vu Luan Dang Chi; Nghia Huynh; Tan Binh Nguyen; Annie Robert; Christiane Vermylen; Jean-Luc Gala
Journal:  Br J Clin Pharmacol       Date:  2015-03       Impact factor: 4.335

8.  Leucopenia resulting from a drug interaction between azathioprine or 6-mercaptopurine and mesalamine, sulphasalazine, or balsalazide.

Authors:  P W Lowry; C L Franklin; A L Weaver; C L Szumlanski; D C Mays; E V Loftus; W J Tremaine; J J Lipsky; R M Weinshilboum; W J Sandborn
Journal:  Gut       Date:  2001-11       Impact factor: 23.059

9.  Phenotyping and genotyping study of thiopurine S-methyltransferase in healthy Chinese children: a comparison of Han and Yao ethnic groups.

Authors:  Jian-ping Zhang; Yong-yuan Guan; Jue-heng Wu; An-long Xu; Shufeng Zhou; Min Huang
Journal:  Br J Clin Pharmacol       Date:  2004-08       Impact factor: 4.335

10.  Genomewide Approach Validates Thiopurine Methyltransferase Activity Is a Monogenic Pharmacogenomic Trait.

Authors:  C Liu; W Yang; D Pei; C Cheng; C Smith; W Landier; L Hageman; Y Chen; J J Yang; K R Crews; N Kornegay; S E Karol; F L Wong; S Jeha; J T Sandlund; R C Ribeiro; J E Rubnitz; M L Metzger; C-H Pui; W E Evans; S Bhatia; M V Relling
Journal:  Clin Pharmacol Ther       Date:  2016-11-18       Impact factor: 6.875

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.